Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $16.75.
FOLD has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th.
Get Our Latest Report on Amicus Therapeutics
Institutional Inflows and Outflows
Amicus Therapeutics Stock Performance
NASDAQ:FOLD opened at $8.86 on Thursday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $12.65. The stock has a market cap of $2.72 billion, a PE ratio of -49.22, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The firm’s fifty day simple moving average is $9.43 and its 200-day simple moving average is $10.25.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
- Five stocks we like better than Amicus Therapeutics
- When to Sell a Stock for Profit or Loss
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- What is a penny stock? A comprehensive guide
- 3 Stocks to Buy While Others Stay on the Sidelines
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.